Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 17 | 2023 | 2313 | 2.000 |
Why?
|
| Stroke Volume | 9 | 2021 | 531 | 1.760 |
Why?
|
| Health Status | 9 | 2021 | 367 | 1.490 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2021 | 140 | 0.920 |
Why?
|
| Health Status Disparities | 2 | 2018 | 275 | 0.870 |
Why?
|
| Aminobutyrates | 3 | 2021 | 10 | 0.820 |
Why?
|
| Neprilysin | 2 | 2019 | 20 | 0.650 |
Why?
|
| Registries | 9 | 2020 | 1605 | 0.600 |
Why?
|
| Tetrazoles | 1 | 2019 | 72 | 0.590 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 358 | 0.580 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 537 | 0.570 |
Why?
|
| Coronary Occlusion | 1 | 2018 | 30 | 0.560 |
Why?
|
| Intermittent Claudication | 1 | 2018 | 49 | 0.560 |
Why?
|
| Ambulatory Care | 2 | 2018 | 400 | 0.540 |
Why?
|
| Health Status Indicators | 1 | 2018 | 111 | 0.530 |
Why?
|
| Guideline Adherence | 2 | 2018 | 390 | 0.490 |
Why?
|
| Dyslipidemias | 1 | 2018 | 251 | 0.460 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 992 | 0.450 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 294 | 0.430 |
Why?
|
| Peripheral Arterial Disease | 1 | 2018 | 318 | 0.430 |
Why?
|
| Embolism | 1 | 2014 | 38 | 0.420 |
Why?
|
| Glucosides | 4 | 2023 | 54 | 0.410 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 515 | 0.400 |
Why?
|
| Benzhydryl Compounds | 4 | 2023 | 77 | 0.400 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 245 | 0.390 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 499 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 770 | 0.370 |
Why?
|
| Valsartan | 3 | 2021 | 26 | 0.360 |
Why?
|
| Brain Ischemia | 1 | 2014 | 268 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 750 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1291 | 0.350 |
Why?
|
| Biphenyl Compounds | 3 | 2021 | 75 | 0.350 |
Why?
|
| Drug Combinations | 3 | 2021 | 273 | 0.340 |
Why?
|
| Aged | 16 | 2023 | 20888 | 0.330 |
Why?
|
| Quality of Life | 7 | 2021 | 2071 | 0.300 |
Why?
|
| Recovery of Function | 4 | 2018 | 442 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2020 | 6421 | 0.290 |
Why?
|
| Hemodynamics | 2 | 2023 | 802 | 0.270 |
Why?
|
| Middle Aged | 14 | 2021 | 28376 | 0.270 |
Why?
|
| Time Factors | 6 | 2020 | 6187 | 0.260 |
Why?
|
| Treatment Outcome | 8 | 2021 | 12856 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 6779 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 1152 | 0.230 |
Why?
|
| Phenylacetates | 2 | 2023 | 27 | 0.230 |
Why?
|
| United States | 7 | 2018 | 11819 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 217 | 0.200 |
Why?
|
| Male | 16 | 2023 | 64524 | 0.200 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1875 | 0.190 |
Why?
|
| Female | 16 | 2023 | 70281 | 0.190 |
Why?
|
| Humans | 21 | 2023 | 130380 | 0.180 |
Why?
|
| Hospitalization | 4 | 2019 | 1927 | 0.180 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 18 | 0.180 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2021 | 46 | 0.180 |
Why?
|
| Cardiotonic Agents | 1 | 2023 | 139 | 0.170 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 172 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 213 | 0.170 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 14 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1443 | 0.150 |
Why?
|
| Patient Admission | 1 | 2020 | 184 | 0.150 |
Why?
|
| Netherlands | 1 | 2018 | 50 | 0.140 |
Why?
|
| Australia | 1 | 2018 | 171 | 0.140 |
Why?
|
| Adrenergic Agonists | 1 | 2017 | 9 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 236 | 0.140 |
Why?
|
| Electric Countershock | 1 | 2017 | 74 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 295 | 0.130 |
Why?
|
| Risk Factors | 4 | 2020 | 10937 | 0.130 |
Why?
|
| Epinephrine | 1 | 2017 | 143 | 0.130 |
Why?
|
| Pneumococcal Vaccines | 1 | 2018 | 174 | 0.130 |
Why?
|
| Social Class | 1 | 2018 | 206 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 4001 | 0.120 |
Why?
|
| Self Care | 1 | 2017 | 226 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 258 | 0.120 |
Why?
|
| Acute Disease | 2 | 2020 | 1151 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 208 | 0.120 |
Why?
|
| Missouri | 1 | 2014 | 41 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 698 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1334 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1231 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 499 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 549 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2017 | 373 | 0.100 |
Why?
|
| Adult | 4 | 2019 | 31121 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1337 | 0.100 |
Why?
|
| Vaccination | 1 | 2018 | 1041 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1203 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2020 | 3680 | 0.090 |
Why?
|
| Disease Progression | 1 | 2018 | 2207 | 0.090 |
Why?
|
| Telemedicine | 1 | 2017 | 511 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3031 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5069 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5186 | 0.080 |
Why?
|
| Survival Rate | 1 | 2014 | 2131 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2920 | 0.070 |
Why?
|
| Incidence | 1 | 2014 | 3328 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2110 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 3395 | 0.040 |
Why?
|
| Placebos | 1 | 2021 | 225 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 324 | 0.040 |
Why?
|
| Young Adult | 1 | 2014 | 9992 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 437 | 0.040 |
Why?
|
| Prognosis | 2 | 2020 | 4894 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2023 | 687 | 0.040 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 45 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 440 | 0.040 |
Why?
|
| Diuretics | 1 | 2019 | 157 | 0.040 |
Why?
|
| Defibrillators | 1 | 2017 | 16 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 312 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1627 | 0.030 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2018 | 88 | 0.030 |
Why?
|
| Telephone | 1 | 2017 | 110 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 429 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 561 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2014 | 17606 | 0.030 |
Why?
|
| Social Behavior | 1 | 2017 | 211 | 0.030 |
Why?
|
| Adolescent | 1 | 2014 | 20749 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 688 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 858 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 220 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 503 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1617 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 438 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1484 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 1547 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1065 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2018 | 700 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3801 | 0.020 |
Why?
|